- Britannia (BLAB) to Launch hair growth trial utilizing CBD formulation
- With sales of over £2.5 billion in 2020, the global hair loss treatment market is expected to grow
- This hair growth initiative is aligned with Britannia’s strategy of utilizing its resources and expertise to build a high-value intellectual property portfolio
- The consumer trial will be managed by ADSL’s existing First Beauty platform
- Britannia Life Sciences Inc. is a global platform offering an integrated suite of services to assist companies along their product development journey
- Britannia Life Sciences Inc. (BLAB) is up 4.55 per cent, trading at C$0.23 at 10:50 am EST
Britannia Life Sciences (BLAB) will be launching a consumer trial to test CBD oil as an ingredient in the treatment of hair loss.
With sales of over £2.5 billion in 2020, the global hair loss treatment market is expected to grow at an annual rate of between four and six per cent through 2027, based on industry estimates.
This hair growth initiative is aligned with Britannia’s strategy of utilizing its resources and expertise to build a high-value intellectual property portfolio while growing the market for CBD by developing a broad range of new applications across a wide range of products.
Britannia has engaged its subsidiary, Advanced Development and Safety Laboratories, to finalize the formulation of a topical cream that utilizes CBD-rich, broad-spectrum hemp oil distillate with the goal of promoting hair growth and density.
The consumer trial will be managed by ADSL’s existing First Beauty platform and will be conducted under the guidance and supervision of health professionals. In its initial phase, trial participants will test a lone topical cream, providing weekly feedback, over a six-month period.
Britannia Life Sciences Inc. is a global platform offering an integrated suite of services to assist companies along their product development journey.
Britannia’s services, including product formulations, safety assessments, analytical and microbiological testing, global compliance and consumer evaluations are offered to companies ranging from multinationals to start-ups particularly in the cosmetics, food and wellness industries.
Britannia has garnered significant expertise in the development and regulatory approval of topical and edible cannabis products, including preparation and support for novel food authorizations.
Britannia Life Sciences Inc. (BLAB) is up 4.55 per cent, trading at C$0.23 at 10:50 am EST.
